Clinical Trial News and Research

RSS

Endoscope: Less invasive alternative to laparoscopic techniques or conventional surgery

Mayo Clinic surgical researchers are reporting a 93 percent success rate in recent animal tests of endoscopic repair of perforated ulcers. The goal is to advance the use of an endoscope -- which allows access to organs through natural openings, such as the mouth -- for a less invasive alternative to laparoscopic techniques (surgery performed through a small incision) or conventional surgery.

15 Oct 2009

Health Sciences South Carolina, Recombinant Data and Sun Microsystems to collaborate on an Integrated Platform for Research

Health Sciences South Carolina (HSSC), today announced that it has selected Recombinant Data Corp. and Sun Microsystems, Inc. to collaborate on the Health Sciences South Carolina Integrated Platform for Research (HS-SCIPR), an unprecedented statewide initiative for translational research and quality improvement.

15 Oct 2009

National Institutes of Health grants $12 million to WCDRC for obesity research

The Miriam Hospital's Weight Control and Diabetes Research Center (WCDRC) recently received six research grants from the National Institutes of Health - totaling more than $12 million in funding - that will support the work of researchers focused on the prevention and treatment of obesity.

15 Oct 2009

Cytheris initiates Phase I/IIa dose escalation study of patients suffering from ICL

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of a Phase I/IIa dose escalation study of patients suffering from idiopathic CD4 lymphocytopenia (ICL).

15 Oct 2009

Marker genes help determine the effectiveness of targeted molecular drug regimen for treating GIST

Analysis of a small number of marker genes may determine in a matter of hours if a patient with gastrointestinal stromal tumors (GIST) would respond to a targeted molecular drug regimen. This analysis could allow clinicians to determine if they have chosen the best course of action or need to consider another alternative.

15 Oct 2009

Curemark commences enrollment in Phase III CM-AT clinical trials for autism treatment

Curemark, LLC, a drug research and development company focused on the treatment of neurological diseases, announced that it has enrolled the first patients in Phase III clinical trials for its autism treatment, CM-AT. The first clinical trial patients have been enrolled at Lake Mary Pediatrics in Orange City, Florida, one of 12 clinical trial sites with a total 170 children across the country.

15 Oct 2009

Interim data from Sanofi Pasteur's Influenza A 2009 Monovalent Vaccine clinical trials in infants and children

Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced today an interim analysis of data from clinical trials of the U.S. licensed Influenza A (H1N1) 2009 Monovalent Vaccine in infants and children 6 months through 9 years of age. The data indicate the vaccine is immunogenic and that one dose may protect many children.

15 Oct 2009

Jazz Pharmaceuticals to present Phase III sodium oxybate trial data at ACR 2009 meetings

Jazz Pharmaceuticals, Inc. announced that data from the company's first Phase III clinical trial of sodium oxybate (JZP-6) for the treatment of fibromyalgia will be presented during the American College of Rheumatology 2009 Annual Meeting (ACR) in Philadelphia, Pennsylvania and also in November during the US Psychiatric and Mental Health Congress (US Psych Congress) in Las Vegas, Nevada.

15 Oct 2009

Positive data from Cardium Therapeutics' Matrix Phase 2b Excellarate trial

Cardium Therapeutics today reported positive data from its Matrix Phase 2b clinical trial of Excellarate(TM) for the potential treatment of patients with chronic non-healing diabetic foot ulcers based on the Company's Gene Activated Matrix (GAM) technology platform.

15 Oct 2009

FDA approves ZyStor Therapeutics' ZC-701 for Phase I human safety trial

ZyStor Therapeutics, Inc., a biotechnology company developing a new class of targeted protein therapeutics for the treatment of Lysosomal Storage Diseases using the Company's proprietary Glycosylation Independent Lysosomal Targeting technology, today announced that it has received clearance from the U. S. Food and Drug Administration to proceed into a clinical trial for its first drug candidate, ZC-701, an enzyme replacement therapy for the treatment of Pompe disease.

14 Oct 2009

EMEA grants ArQule's ARQ 197 orphan drug designation

ArQule, Inc. today announced that the European Medicines Evaluation Agency (EMEA) has designated ARQ 197 as an orphan medical product for the treatment of soft tissue sarcoma.

14 Oct 2009

Progenics Pharmaceuticals and Wyeth Pharmaceuticals sign license agreement

Progenics Pharmaceuticals, Inc. today announced that it has entered into an agreement with Wyeth Pharmaceuticals, a division of Wyeth under which Progenics is regaining all worldwide rights to the RELISTOR® franchise from Wyeth Pharmaceuticals, which Progenics had previously licensed to Wyeth Pharmaceuticals.

14 Oct 2009

Women with breast cancer can improve their mental health through Transcendental Meditation technique

Women with breast cancer reduced stress and improved their mental health and emotional well being through the Transcendental Meditation technique, according to a new study published in the current issue of the peer-reviewed Integrative Cancer Therapies (Vol. 8, No. 3: September 2009).

14 Oct 2009

Breakthrough in pancreatic cancer treatment

Epeius Biotechnologies (www.epeiusbiotech.com) confirms the first real breakthrough for pancreatic cancer seen in years; publishes a landmark report of tumor-targeted Rexin-G as stand-alone therapy in chemotherapy-resistant pancreatic cancer.

14 Oct 2009

Antisense Therapeutics completes repeat-dosing toxicology studies for ATL1103

Antisense Therapeutics Limited is pleased to announce that the Company has now completed repeat-dosing toxicology studies for ATL1103 in two species -- mouse and non-human primate. Draft study reports from the study contractors in the United States have been received, and the toxicology outcomes from these studies support ANP's plans for the continued development of ATL1103.

14 Oct 2009

FDA recommends approval for UI Pharmaceuticals to manufacture an aseptically filled sterile drug product

In September 2009, the Kansas City District Office of the Food and Drug Administration (FDA) submitted a recommendation of approval to the Center for Drug Evaluation and Research for The University of Iowa Pharmaceuticals (UIP) to manufacture and test an aseptically filled, sterile prescription drug product for a commercial client. The drug product contains a new chemical entity and is a sterile solution that is aseptically filled into vials.

14 Oct 2009

Endovascular procedure for abdominal aortic aneurysm may reduce mortality rate

Patients who received the less-invasive endovascular repair of an abdominal aortic aneurysm had a lower risk of death in the first 30 days after the procedure compared to patients who an open repair, but both procedures had similar rates of death after two years, according to a study in the October 14 issue of JAMA, a theme issue on surgical care.

14 Oct 2009

Increase in adiponectin hormone levels protects against sepsis-related mortality

A hormone naturally found in the fat that surrounds the abdominal organs for the first time has been linked to death related to sepsis, surgeons reported at the 2009 Clinical Congress of the American College of Surgeons. A study exhibited at the conference showed that low levels of the hormone adiponectin placed animals at a profoundly high risk of death from a septic insult.

14 Oct 2009

Study shows elevated levels of antioxidant urate can slow the progression of Parkinson's disease

By examining data from a 20-year-old clinical trial, a research team based at the MassGeneral Institute for Neurodegenerative Diseases (MGH-MIND) and Harvard School of Public Health (HSPH), has found evidence supporting the findings of their 2008 study - that elevated levels of the antioxidant urate may slow the progression of Parkinson's disease.

14 Oct 2009

ADDF grant to support the evaluation of PPAR-sparing insulin sensitizers

Metabolic Solutions Development Company (MSDC) announced today that it has received a $100,000 grant from the Alzheimer's Drug Discovery Foundation (ADDF) to support the evaluation of PPAR-sparing insulin sensitizers as a potential treatment for Alzheimer's disease.

14 Oct 2009

Clinical Trial News and Research

Endoscope: Less invasive alternative to laparoscopic techniques or conventional surgery

Health Sciences South Carolina, Recombinant Data and Sun Microsystems to collaborate on an Integrated Platform for Research

National Institutes of Health grants $12 million to WCDRC for obesity research

Cytheris initiates Phase I/IIa dose escalation study of patients suffering from ICL

Marker genes help determine the effectiveness of targeted molecular drug regimen for treating GIST

Curemark commences enrollment in Phase III CM-AT clinical trials for autism treatment

Interim data from Sanofi Pasteur's Influenza A 2009 Monovalent Vaccine clinical trials in infants and children

Jazz Pharmaceuticals to present Phase III sodium oxybate trial data at ACR 2009 meetings

Positive data from Cardium Therapeutics' Matrix Phase 2b Excellarate trial

FDA approves ZyStor Therapeutics' ZC-701 for Phase I human safety trial

EMEA grants ArQule's ARQ 197 orphan drug designation

Progenics Pharmaceuticals and Wyeth Pharmaceuticals sign license agreement

Women with breast cancer can improve their mental health through Transcendental Meditation technique

Breakthrough in pancreatic cancer treatment

Antisense Therapeutics completes repeat-dosing toxicology studies for ATL1103

FDA recommends approval for UI Pharmaceuticals to manufacture an aseptically filled sterile drug product

Endovascular procedure for abdominal aortic aneurysm may reduce mortality rate

Increase in adiponectin hormone levels protects against sepsis-related mortality

Study shows elevated levels of antioxidant urate can slow the progression of Parkinson's disease

ADDF grant to support the evaluation of PPAR-sparing insulin sensitizers

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News